Chimeric Therapeutics : AGM Presentation

ersonal use only

Annual General Meeting

Corporate Update I November 22, 2021

CHIMERIC THERAPEUTICS CORPORATE SNAPSHOT

only	The ASX leader in cell therapy as the only clinical
	stage cell therapy company
	Lead asset, CHM 1101 (CLTX CAR T) advancing in
use	a phase 1 clinical trial with promising early
clinical data
CHM 2101 (CDH17 CAR T) making rapid progress
	to Phase 1 in 2022
ersonal	Further advancing pipeline development with
innovative cell therapies
	Industry leading expertise and experience in cell
	therapy development

Founded in 2020 and listed on the ASX (CHM) in

January 2021 with an oversubscribed raise of $35M

	0.4							0.37
	0.35		0.31	0.32			0.31	0.34	0.32
	0.3			0.28	0.27			0.31
($)
0.25
AUS
0.2
Price	0.2
0.15
Share
0.1
0.05
	0
	January	February March	April	May	June	July August September October
Market Cap: AUS ~$110M		Net Cash: AUS $18M (Sept 21)
Shares on Issue:	330 M			Board / Mgmt. Ownership: 30%

OUR MISSION

To Bring the Promise of Cell Therapy to Life

ersonal use only

Traditional drug development focuses on delaying disease progression- not on a cure.

We believe that novel cellular therapies have the promise to cure cancer.

Our mission is to to bring that

promise to life for more

patients with cancer.

"With about 6 months to live, I got a call asking if I wanted to join a CAR T clinical trial. I believe that call saved my life."

Dimas Padilla

Cancer Survivor

CELL THERAPY INVESTMENT LANDSCAPE

Cell therapy is the most active investment sector in biotech today with ~$20B in

only	financing in 2020
ACQUISITIONS
use	Gilead acquisition	$11.9B
of Kite
	Celgene acquisition	$9B
	of Juno
ersonal	Astellas acquisition	$665M
of Xyphos
	Kite acquisition of	$567M
	Cell Design Labs

The global market for cell therapies

is estimated to reach between

USD $8-9 billion by 2026

PARTNERSHIPS

Janssen & Fate	$3B
Kite & Shoreline	$2.3B
Vertex & CRISPR	$900M
Eli Lilly & Precision	$525M
Merck & Artiva	$1.8B
Roche &	$3B
Adaptimmune

In the past 18-24 months, 16 of the largest

pharmaceutical companies have added cell and

gene therapy products to their portfolio

	IPO's
Sana Biotech	$675M
Lyell	$425M
CARsgen	$400M
Instil Bio	$368M
Graphite Bio	$273M
Century Tx	$243M

4

CHIMERIC PORTFOLIO DEVELOPMENT STRATEGY

Focused on building a diversified cell therapy pipeline with cutting edge innovation

ersonal use only

Novel Designs

T Cells	Alternative	NK Cells
Cell Types

Individualized		Alternative		Off the Shelf
(autologous)		Cell Sources		(allogeneic)